The Future of Gene Therapy: Revolutionizing Modern Medicine
Article Sidebar
Page Numbers:
163-168
Digital Object Identifier:
10.58578/ajbmbr.v2i2.5326
Viewed: 761 times
Downloaded: 208 times
LYAS Publisher cordially invites qualified professionals to serve as Editors or Reviewers. Your expertise will make an important contribution to maintaining and strengthening the academic quality of our publications. Interested applicants are kindly requested to complete the application form at the following link: Editors & Reviewers
Please feel free to contact us if you need any further information about the submission process or if you have any additional questions.
Authors:
Muhammad Akram1, Alam Afroz Urooj Khan2, Isaac John Umaru3 
Copyright :
Authors retain copyright and grant the journal right of first publication.
Main Article Content
Abstract
The use of gene therapy paired with advanced technology may one day enable chronic illnesses, cancerous diseases, and even genetic defects to be treated via DNA alterations. With developments and promising results in gene CRISPR-Cas9 editing technology, improved treatments and promising results from clinical trials have made gene therapy a possibility. It is also predicted that gene therapy will be used in the future to combat heart issues, cancer, neurological diseases, and other hereditary attributes. Nonetheless, metastatic issues pertaining to ethics, engagement, spending, and the probability of negative consequences over time still remain. In the case of augmented medicine, incorporating stem cells with new artificial intelligence technology will ensure better and more accurate treatment along with greater personalization of gene therapies. This is expected to lead to a whole new realm of precision medicine.
Citation Metrics:
Downloads
Article Details
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
References
Gordon, K., Del Medico, A., Sander, I., Kumar, A., & Hamad, B. (2019). Gene therapies in ophthalmic diseases. Nature Reviews Drug Discovery, 18, 415-416.
Hussen, B. M., Taheri, M., Yashooa, R. K., Abdullah, G. H., Abdullah, S. R., Kheder, R. K., & Mustafa, S. A. (2024). Revolutionizing medicine: Recent developments and future prospects in stem-cell therapy. International Journal of Surgery, 110(12), 8002-8024
Jensen, T. L., Gøtzsche, C. R., & Woldbye, D. P. (2021). Current and future prospects for gene therapy for rare genetic diseases affecting the brain and spinal cord. Frontiers in Molecular Neuroscience, 14, 695937.
Lambricht, L., Lopes, A., Kos, S., Sersa, G., Préat, V., & Vandermeulen, G. (2016). Clinical potential of electroporation for gene therapy and DNA vaccine delivery. Expert Opinion on Drug Delivery, 13(2), 295-310.
Lappé, M. (1991). Ethical issues in manipulating the human germ line. The Journal of Medicine and Philosophy, 16(6), 621-639
Mehta, P., & Bhayani, D. (2017). Impact of space environment on stability of medicines: Challenges and prospects. Journal of Pharmaceutical and Biomedical Analysis, 136, 111-119.
Pantiya, P., Thonusin, C., Chattipakorn, N., & Chattipakorn, S. C. (2020). Mitochondrial abnormalities in neurodegenerative models and possible interventions: Focus on Alzheimer's disease, Parkinson's disease, Huntington's disease. Mitochondrion, 55, 14-47.
Salzman, R., Cook, F., Hunt, T., Malech, H. L., Reilly, P., Foss-Campbell, B., & Barrett, D. (2018). Addressing the value of gene therapy and enhancing patient access to transformative treatments. Molecular Therapy, 26(12), 2717-2726.
Zhu, K., & Jin, Y. (2023). Case report: A case of SLC26A4 mutations causing Pendred syndrome and non-cystic fibrosis bronchiectasis. Frontiers in Pediatrics, 10, 1077878.
Wong, C. H., Li, D., Wang, N., Gruber, J., Conti, R. M., & Lo, A. W. (2021). Estimating the financial impact of gene therapy in the US (Working Paper No. 28744). National Bureau of Economic